Trade Biomerieux - BIM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.55 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.017913% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.004309% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Biomerieux SA ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 100.05 |
| Open* | 100.85 |
| 1-Year Change* | 6.1% |
| Day's Range* | 100.7 - 101.3 |
| 52 wk Range | 77.48-109.20 |
| Average Volume (10 days) | 134.40K |
| Average Volume (3 months) | 2.07M |
| Market Cap | 11.91B |
| P/E Ratio | 26.34 |
| Shares Outstanding | 118.00M |
| Revenue | 3.59B |
| EPS | 3.82 |
| Dividend (Yield %) | 0.84493 |
| Beta | -0.04 |
| Next Earnings Date | Sep 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 100.05 | 0.60 | 0.60% | 99.45 | 100.60 | 98.10 |
| Mar 23, 2023 | 99.35 | 1.50 | 1.53% | 97.85 | 99.80 | 97.15 |
| Mar 22, 2023 | 97.60 | 0.20 | 0.21% | 97.40 | 98.45 | 96.25 |
| Mar 21, 2023 | 97.30 | -0.90 | -0.92% | 98.20 | 98.30 | 96.90 |
| Mar 20, 2023 | 97.45 | 0.85 | 0.88% | 96.60 | 99.15 | 96.00 |
| Mar 17, 2023 | 96.60 | -0.15 | -0.16% | 96.75 | 97.25 | 95.85 |
| Mar 16, 2023 | 95.80 | 0.50 | 0.52% | 95.30 | 96.45 | 93.60 |
| Mar 15, 2023 | 93.90 | -1.05 | -1.11% | 94.95 | 95.10 | 92.85 |
| Mar 14, 2023 | 94.95 | 1.20 | 1.28% | 93.75 | 95.75 | 93.35 |
| Mar 13, 2023 | 93.40 | 0.00 | 0.00% | 93.40 | 93.95 | 91.65 |
| Mar 10, 2023 | 94.05 | -2.25 | -2.34% | 96.30 | 96.50 | 93.80 |
| Mar 9, 2023 | 96.45 | 2.75 | 2.93% | 93.70 | 97.45 | 93.35 |
| Mar 8, 2023 | 93.50 | 2.45 | 2.69% | 91.05 | 93.55 | 90.20 |
| Mar 7, 2023 | 91.85 | -0.95 | -1.02% | 92.80 | 93.70 | 91.25 |
| Mar 6, 2023 | 92.30 | -0.55 | -0.59% | 92.85 | 93.10 | 92.00 |
| Mar 3, 2023 | 92.75 | 0.75 | 0.82% | 92.00 | 93.10 | 91.50 |
| Mar 2, 2023 | 91.25 | 1.30 | 1.45% | 89.95 | 91.45 | 89.85 |
| Mar 1, 2023 | 90.80 | -1.60 | -1.73% | 92.40 | 92.60 | 90.25 |
| Feb 28, 2023 | 92.50 | -0.25 | -0.27% | 92.75 | 93.25 | 92.00 |
| Feb 27, 2023 | 93.35 | -0.05 | -0.05% | 93.40 | 93.85 | 92.90 |
Biomerieux Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
| Revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
| Cost of Revenue, Total | 1580.4 | 1375.4 | 1364.5 | 1208.2 | 1119 |
| Gross Profit | 2008.7 | 2000.8 | 1753.7 | 1466.6 | 1302.3 |
| Total Operating Expense | 3001.9 | 2591.3 | 2566 | 2304.1 | 2075.2 |
| Selling/General/Admin. Expenses, Total | 954.7 | 815.6 | 789.3 | 749.8 | 643.1 |
| Research & Development | 446.6 | 385.8 | 398.8 | 374.3 | 326.9 |
| Depreciation / Amortization | 76.6 | 59.7 | 17.5 | 17.9 | 17.5 |
| Unusual Expense (Income) | -0.6 | 0.6 | |||
| Other Operating Expenses, Total | -56.4 | -44.6 | -4.7 | -46.1 | -31.3 |
| Operating Income | 587.2 | 784.9 | 552.2 | 370.7 | 346.1 |
| Interest Income (Expense), Net Non-Operating | -4.3 | -11.7 | -29.1 | -23.8 | -26.7 |
| Other, Net | -2.3 | 1.3 | 1.2 | 0.7 | -1.9 |
| Net Income Before Taxes | 580.6 | 774.5 | 524.3 | 347.6 | 317.5 |
| Net Income After Taxes | 440.5 | 598.9 | 402.8 | 269.8 | 252.4 |
| Minority Interest | 11.8 | 2.9 | 1.7 | 3.1 | 1.1 |
| Equity In Affiliates | 0 | -0.7 | -0.2 | 0 | 0.2 |
| Net Income Before Extra. Items | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
| Net Income | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
| Total Adjustments to Net Income | 0.1 | 0 | 0.1 | -0.1 | 2.8 |
| Income Available to Common Excl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Income Available to Common Incl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Diluted Net Income | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
| Diluted Weighted Average Shares | 118.441 | 118.893 | 118.592 | 118.609 | 118.203 |
| Diluted EPS Excluding Extraordinary Items | 3.81964 | 5.05579 | 3.41 | 2.3 | 2.17 |
| Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.62 | 0.19 | 0.35 |
| Diluted Normalized EPS | 3.81964 | 5.05189 | 3.41389 | 2.3 | 2.17 |
| Dilution Adjustment | 0 |
| Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
|---|---|---|---|---|
| Total revenue | 1931.1 | 1658 | 1802 | 1574.2 |
| Revenue | 1931.1 | 1658 | 1802 | 1574.2 |
| Cost of Revenue, Total | 860.4 | 720 | 721.6 | 659.2 |
| Gross Profit | 1070.7 | 938 | 1080.4 | 915 |
| Total Operating Expense | 1641 | 1360.9 | 1383.5 | 1208.4 |
| Selling/General/Admin. Expenses, Total | 514.4 | 440.3 | 436.9 | 379.6 |
| Research & Development | 239.3 | 207.3 | 204.8 | 181.5 |
| Depreciation / Amortization | 51.7 | 24.9 | 44.6 | 8.3 |
| Other Operating Expenses, Total | -24.8 | -31.6 | -24.4 | -20.2 |
| Operating Income | 290.1 | 297.1 | 418.5 | 365.8 |
| Interest Income (Expense), Net Non-Operating | 2.8 | -7.1 | -4.7 | -7 |
| Other, Net | -3.8 | 1.5 | 1.3 | 0.6 |
| Net Income Before Taxes | 289.1 | 291.5 | 415.1 | 359.4 |
| Net Income After Taxes | 214.2 | 226.3 | 322 | 276.9 |
| Minority Interest | 10 | 1.8 | 1.8 | 1.1 |
| Equity In Affiliates | 0 | 0 | 0.2 | -0.9 |
| Net Income Before Extra. Items | 224.2 | 228.1 | 324 | 277.1 |
| Net Income | 224.2 | 228.1 | 324 | 277.1 |
| Income Available to Common Excl. Extra. Items | 224.4 | 228 | 324 | 277.1 |
| Income Available to Common Incl. Extra. Items | 224.4 | 228 | 324 | 277.1 |
| Diluted Net Income | 224.4 | 228 | 324 | 277.1 |
| Diluted Weighted Average Shares | 118.533 | 118.349 | 119.1 | 118.927 |
| Diluted EPS Excluding Extraordinary Items | 1.89315 | 1.92651 | 2.7204 | 2.33 |
| Dividends per Share - Common Stock Primary Issue | 0.85 | 0 | 0.85 | 0 |
| Diluted Normalized EPS | 1.89315 | 1.92651 | 2.7204 | 2.33 |
| Total Adjustments to Net Income | 0.2 | -0.1 | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 2199.2 | 1661.6 | 1438.5 | 1314.4 | 1279.4 |
| Cash and Short Term Investments | 803.5 | 389.2 | 275 | 288.3 | 312.1 |
| Cash | 547.1 | 313.5 | 241 | 239.9 | 214.4 |
| Cash & Equivalents | 256.4 | 75.7 | 34 | 48.4 | 97.7 |
| Total Receivables, Net | 761 | 730.4 | 668.8 | 607.3 | 587 |
| Accounts Receivable - Trade, Net | 590.6 | 597.9 | 552.1 | 491.8 | 460.1 |
| Total Inventory | 634.6 | 541.9 | 494.7 | 418.8 | 380.3 |
| Other Current Assets, Total | 0.1 | 0.1 | |||
| Total Assets | 4616.8 | 3927.8 | 3781.9 | 3501.6 | 2990 |
| Property/Plant/Equipment, Total - Net | 1224.8 | 1068.6 | 1025.2 | 899.1 | 711.4 |
| Property/Plant/Equipment, Total - Gross | 2447.6 | 2173.3 | 2100.9 | 1899.4 | 1594.4 |
| Accumulated Depreciation, Total | -1222.7 | -1104.7 | -1075.7 | -1000.5 | -883.1 |
| Goodwill, Net | 669.5 | 629.4 | 652.5 | 619 | 442.7 |
| Intangibles, Net | 411.5 | 430.7 | 508.4 | 507.2 | 430.7 |
| Long Term Investments | 34.5 | 39.9 | 31.7 | 59.2 | 50.9 |
| Note Receivable - Long Term | 27.5 | 10.7 | 10.4 | 8 | 7 |
| Other Long Term Assets, Total | 49.8 | 86.9 | 115.2 | 94.7 | 67.9 |
| Total Current Liabilities | 955.8 | 923.8 | 1170.1 | 796.3 | 651.8 |
| Accounts Payable | 239.5 | 207.1 | 211.9 | 179.7 | 161.3 |
| Accrued Expenses | 317.9 | 327.4 | 283.3 | 262.4 | 219.3 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 99.7 | 128.9 | 438.6 | 129.1 | 76.9 |
| Other Current Liabilities, Total | 298.7 | 260.4 | 236.3 | 225.1 | 194.3 |
| Total Liabilities | 1493.6 | 1496.7 | 1578 | 1572.8 | 1252.4 |
| Total Long Term Debt | 362.8 | 352.4 | 153.7 | 524.9 | 391.1 |
| Long Term Debt | 362.8 | 352.4 | 153.7 | 524.9 | 391.1 |
| Deferred Income Tax | 61.1 | 105.8 | 141.2 | 130.5 | 103.8 |
| Minority Interest | 51.4 | 50.2 | 50.7 | 74.1 | -0.9 |
| Other Liabilities, Total | 62.5 | 64.5 | 62.3 | 47 | 106.6 |
| Total Equity | 3123.2 | 2431.1 | 2203.9 | 1928.8 | 1737.6 |
| Common Stock | 12 | 12 | 12 | 12 | 12 |
| Additional Paid-In Capital | 2242.3 | 2204.7 | 1933.4 | 1712.2 | 1558.3 |
| Retained Earnings (Accumulated Deficit) | 542.5 | 344.7 | 207.9 | 210.1 | 184.1 |
| Treasury Stock - Common | -10.3 | -23 | -3.9 | -32.8 | -10.9 |
| Other Equity, Total | 336.7 | -107.3 | 54.5 | 27.3 | -5.9 |
| Total Liabilities & Shareholders’ Equity | 4616.8 | 3927.8 | 3781.9 | 3501.6 | 2990 |
| Total Common Shares Outstanding | 118.282 | 118.16 | 118.324 | 117.819 | 118.132 |
| Dec 2021 | Jun 2021 | |
|---|---|---|
| Total Current Assets | 2199.2 | 1798.7 |
| Cash and Short Term Investments | 803.5 | 493.2 |
| Cash | 547.1 | 363.3 |
| Cash & Equivalents | 256.4 | 129.9 |
| Total Receivables, Net | 761 | 694.5 |
| Accounts Receivable - Trade, Net | 590.6 | 542.4 |
| Total Inventory | 634.6 | 611 |
| Total Assets | 4616.8 | 4157.2 |
| Property/Plant/Equipment, Total - Net | 1224.8 | 1135.2 |
| Property/Plant/Equipment, Total - Gross | 2447.6 | 2306.1 |
| Accumulated Depreciation, Total | -1222.7 | -1170.8 |
| Goodwill, Net | 669.5 | 642.4 |
| Intangibles, Net | 411.5 | 426.8 |
| Long Term Investments | 62 | 56.6 |
| Other Long Term Assets, Total | 49.8 | 97.5 |
| Total Current Liabilities | 955.8 | 857.9 |
| Accounts Payable | 239.5 | 199.1 |
| Notes Payable/Short Term Debt | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 99.7 | 163.2 |
| Other Current Liabilities, Total | 616.6 | 495.6 |
| Total Liabilities | 1493.6 | 1459 |
| Total Long Term Debt | 362.8 | 361.5 |
| Long Term Debt | 362.8 | 361.5 |
| Deferred Income Tax | 61.1 | 124.7 |
| Minority Interest | 51.4 | 50.8 |
| Other Liabilities, Total | 62.5 | 64.1 |
| Total Equity | 3123.2 | 2698.2 |
| Common Stock | 12 | 12 |
| Additional Paid-In Capital | 2242.3 | 2528.8 |
| Retained Earnings (Accumulated Deficit) | 542.5 | 219.5 |
| Treasury Stock - Common | -10.3 | -16.6 |
| Other Equity, Total | 336.7 | -45.5 |
| Total Liabilities & Shareholders’ Equity | 4616.8 | 4157.2 |
| Total Common Shares Outstanding | 118.282 | 118.095 |
| Other Current Assets, Total | 0.1 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 598.2 | 402.7 | 269.7 | 255.6 | 237.5 |
| Cash From Operating Activities | 811.1 | 582.8 | 407.9 | 399.7 | 341.3 |
| Cash From Operating Activities | 231 | 210.8 | 189.5 | 177 | 140.5 |
| Non-Cash Items | 4.6 | 159 | 45.5 | 12.3 | 31.9 |
| Cash Taxes Paid | 185.4 | 115.9 | 81.6 | 66.5 | 91.5 |
| Cash Interest Paid | |||||
| Changes in Working Capital | -22.7 | -189.7 | -96.8 | -45.2 | -68.6 |
| Cash From Investing Activities | -307.3 | -265.2 | -282.2 | -413.1 | -180.4 |
| Capital Expenditures | -290.1 | -277.5 | -272.5 | -226.4 | -183.5 |
| Other Investing Cash Flow Items, Total | -17.2 | 12.3 | -9.7 | -186.7 | 3.1 |
| Cash From Financing Activities | -127 | -176.2 | -133.9 | 43 | -52.5 |
| Financing Cash Flow Items | 0 | -2.4 | -23.4 | 0 | -11.6 |
| Total Cash Dividends Paid | -73.1 | -22.5 | -41.3 | -40.2 | -39.4 |
| Issuance (Retirement) of Stock, Net | -3.8 | -16.8 | 0 | -22.3 | -0.9 |
| Issuance (Retirement) of Debt, Net | -50.1 | -134.5 | -69.2 | 105.5 | -0.6 |
| Foreign Exchange Effects | 39.2 | -34.1 | -6.1 | -11.8 | 5.4 |
| Net Change in Cash | 416 | 107.3 | -14.3 | 17.8 | 113.8 |
| Dec 2021 | Jun 2021 | |
|---|---|---|
| Net income/Starting Line | 598.2 | 276 |
| Cash From Operating Activities | 811.1 | 285.8 |
| Cash From Operating Activities | 231 | 97.2 |
| Non-Cash Items | 4.6 | -66.4 |
| Cash Taxes Paid | 185.4 | 98.1 |
| Changes in Working Capital | -22.7 | -21 |
| Cash From Investing Activities | -307.3 | -143.4 |
| Capital Expenditures | -290.1 | -143.5 |
| Other Investing Cash Flow Items, Total | -17.2 | 0.1 |
| Cash From Financing Activities | -127 | -73.8 |
| Total Cash Dividends Paid | -73.1 | -73.1 |
| Issuance (Retirement) of Stock, Net | -3.8 | -2.5 |
| Issuance (Retirement) of Debt, Net | -50.1 | 1.8 |
| Foreign Exchange Effects | 39.2 | 12.8 |
| Net Change in Cash | 416 | 81.4 |
| Financing Cash Flow Items | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Mérieux Family | Other Insider Investor | 58.9047 | 69720270 | 0 | 2022-12-13 | LOW |
| Dassault Family | Other Insider Investor | 4.5964 | 5440410 | 0 | 2022-12-13 | LOW |
| Sofina S.A. | Investment Advisor/Hedge Fund | 1.7293 | 2046857 | 0 | 2022-12-13 | LOW |
| Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 1.257 | 1487841 | -6384 | 2023-01-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.0154 | 1201783 | 1769 | 2023-02-28 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 1.0018 | 1185794 | -25925 | 2023-01-31 | HIGH |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.853 | 1009582 | -23564 | 2022-12-31 | LOW |
| Biomérieux Employees | Corporation | 0.7268 | 860200 | 0 | 2022-12-13 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.67 | 793019 | -82179 | 2023-02-28 | LOW |
| La Financière de l'Echiquier | Investment Advisor | 0.6011 | 711499 | -9 | 2022-11-30 | LOW |
| DNCA Investments | Investment Advisor | 0.5926 | 701399 | 103035 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.5746 | 680070 | -1913 | 2022-12-31 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.5726 | 677721 | 2464 | 2023-02-28 | HIGH |
| Devon Equity Management Ltd. | Investment Advisor | 0.5578 | 660181 | -41600 | 2023-01-31 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.4724 | 559089 | -8162 | 2023-02-28 | LOW |
| Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.4028 | 476806 | -31331 | 2022-11-30 | LOW |
| Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.361 | 427323 | 13611 | 2023-01-31 | LOW |
| AXA Investment Managers Paris | Investment Advisor/Hedge Fund | 0.3321 | 393119 | 9376 | 2023-01-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.3259 | 385689 | -259 | 2023-01-31 | LOW |
| Stewart Investors | Investment Advisor | 0.2828 | 334721 | -152 | 2022-08-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Biomerieux Company profile
About BioMerieux SA
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.
Equity composition
9/2017, 3-for-1 stock split (Factor: 3).
| Industry: | Laboratory Diagnostic & Testing Substances |
376, chemin de l'Orme
69280
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com